{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:46:14Z","timestamp":1789865174139,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"40-41","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.vaccine.2006.06.002","type":"journal-article","created":{"date-parts":[[2006,6,20]],"date-time":"2006-06-20T07:26:11Z","timestamp":1150788371000},"page":"6405-6413","source":"Crossref","is-referenced-by-count":31,"title":["Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli"],"prefix":"10.1016","volume":"24","author":[{"given":"Brian R.","family":"Sloat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengrong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2006.06.002_bib1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/jb.176.3.586-595.1994","article-title":"Regulation of the Bacillus anthracis protective antigen gene: CO2 and a trans-acting element activate transcription from one of two promoters","volume":"176","author":"Koehler","year":"1994","journal-title":"J Bacteriol"},{"issue":"11","key":"10.1016\/j.vaccine.2006.06.002_bib2","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199909093411107","article-title":"Anthrax","volume":"341","author":"Dixon","year":"1999","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.vaccine.2006.06.002_bib3","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2006.06.002_bib4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1128\/AEM.11.4.330-334.1963","article-title":"Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures","volume":"11","author":"Puziss","year":"1963","journal-title":"Appl Microbiol"},{"issue":"6860","key":"10.1016\/j.vaccine.2006.06.002_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/n35101999","article-title":"Identification of the cellular receptor for anthrax toxin","volume":"414","author":"Bradley","year":"2001","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2006.06.002_bib6","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0014-5793(02)03609-8","article-title":"Anthrax toxin: a tripartite lethal combination","volume":"531","author":"Ascenzi","year":"2002","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.vaccine.2006.06.002_bib7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/IAI.70.2.661-664.2002","article-title":"Anthrax spores make an essential contribution to vaccine efficacy","volume":"70","author":"Brossier","year":"2002","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2006.06.002_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-9433-4-4","article-title":"Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin","volume":"4","author":"Wang","year":"2005","journal-title":"Med Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2006.06.002_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1006\/mpat.1993.1037","article-title":"Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence","volume":"14","author":"Welkos","year":"1993","journal-title":"Microb Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2006.06.002_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0882-4010(91)90053-D","article-title":"Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis","volume":"10","author":"Welkos","year":"1991","journal-title":"Microb Pathog"},{"issue":"19","key":"10.1016\/j.vaccine.2006.06.002_bib11","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1073\/pnas.1834478100","article-title":"A dually active anthrax vaccine that confers protection against both bacilli and toxins","volume":"100","author":"Rhie","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"10.1016\/j.vaccine.2006.06.002_bib12","doi-asserted-by":"crossref","first-page":"8945","DOI":"10.1073\/pnas.1633512100","article-title":"Poly(gamma-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine","volume":"100","author":"Schneerson","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.vaccine.2006.06.002_bib13","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1074\/jbc.M509432200","article-title":"Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy","volume":"281","author":"Joyce","year":"2006","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.vaccine.2006.06.002_bib14","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1073\/pnas.0401351101","article-title":"mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia","volume":"101","author":"Kozel","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.vaccine.2006.06.002_bib15","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.vaccine.2004.05.029","article-title":"Anthrax capsule vaccine protects against experimental infection","volume":"23","author":"Chabot","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2006.06.002_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1086\/426865","article-title":"Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms","volume":"191","author":"Mikszta","year":"2005","journal-title":"J Infect Dis"},{"issue":"32","key":"10.1016\/j.vaccine.2006.06.002_bib17","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2006.06.002_bib18","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1128\/IAI.70.4.2022-2028.2002","article-title":"Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice","volume":"70","author":"Flick-Smith","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.06.002_bib19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2006.06.002_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4049\/jimmunol.163.1.57","article-title":"Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells","volume":"163","author":"Verdijk","year":"1999","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2006.06.002_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4049\/jimmunol.172.1.138","article-title":"APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA","volume":"172","author":"Schmidt","year":"2004","journal-title":"J Immunol"},{"issue":"27","key":"10.1016\/j.vaccine.2006.06.002_bib22","doi-asserted-by":"crossref","first-page":"10116","DOI":"10.1073\/pnas.0403744101","article-title":"CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells","volume":"101","author":"Sivori","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.vaccine.2006.06.002_bib23","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.4049\/jimmunol.172.10.6065","article-title":"Toll-like receptor ligands directly promote activated CD4+ T cell survival","volume":"172","author":"Gelman","year":"2004","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.06.002_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.cji.0000156828.75196.0d","article-title":"Defining the antigen-specific T-cell response to vaccination and poly(I:C)\/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity","volume":"28","author":"Salem","year":"2005","journal-title":"J Immunother"},{"issue":"7028","key":"10.1016\/j.vaccine.2006.06.002_bib25","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nature03326","article-title":"Toll-like receptor 3 promotes cross-priming to virus-infected cells","volume":"433","author":"Schulz","year":"2005","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.vaccine.2006.06.002_bib26","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1128\/JVI.79.5.2910-2919.2005","article-title":"Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection","volume":"79","author":"Ichinohe","year":"2005","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.vaccine.2006.06.002_bib27","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/eji.200425676","article-title":"The binding affinity of double-stranded RNA motifs to HIV-1 Tat protein affects transactivation and the neutralizing capacity of anti-Tat antibodies elicited after intranasal immunization","volume":"35","author":"Partidos","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2006.06.002_bib28","article-title":"Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic\u2013polyribocytidylic acid induced strong mucosal and systemic immunities","author":"Sloat","year":"2006","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.vaccine.2006.06.002_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/(SICI)1097-0290(19990405)63:1<110::AID-BIT11>3.0.CO;2-T","article-title":"Biosynthesis and ultrasonic degradation of bacterial poly(gamma-glutamic acid)","volume":"63","author":"Perez-Camero","year":"1999","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"10.1016\/j.vaccine.2006.06.002_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/JB.180.1.52-58.1998","article-title":"The capsule and S-layer: two independent and yet compatible macromolecular structures in Bacillus anthracis","volume":"180","author":"Mesnage","year":"1998","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.06.002_bib31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/jb.171.2.722-730.1989","article-title":"Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis","volume":"171","author":"Makino","year":"1989","journal-title":"J Bacteriol"},{"issue":"11","key":"10.1016\/j.vaccine.2006.06.002_bib32","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.4049\/jimmunol.170.11.5636","article-title":"Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen","volume":"170","author":"Boyaka","year":"2003","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2006.06.002_bib33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11095-005-9078-7","article-title":"Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome\u2013protamine\u2013DNA particles","volume":"23","author":"Sloat","year":"2006","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2006.06.002_bib34","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-3659(02)00051-2","article-title":"Topical immunization using nanoengineered genetic vaccines","volume":"81","author":"Cui","year":"2002","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2006.06.002_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev.micro.55.1.647","article-title":"Anthrax","volume":"55","author":"Mock","year":"2001","journal-title":"Annu Rev Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2006.06.002_bib36","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0928-8244(03)00366-3","article-title":"Induction of opsonic antibodies to the gamma-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide\u2013carrier protein conjugate","volume":"40","author":"Wang","year":"2004","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2006.06.002_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0169-409X(01)00162-4","article-title":"Nasal vaccines","volume":"51","author":"Davis","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"issue":"Pt 6","key":"10.1016\/j.vaccine.2006.06.002_bib38","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1099\/00221287-147-6-1677","article-title":"The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores","volume":"147","author":"Welkos","year":"2001","journal-title":"Microbiology"},{"issue":"10","key":"10.1016\/j.vaccine.2006.06.002_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/0022-1317-51-10-821","article-title":"In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody","volume":"51","author":"Welkos","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2006.06.002_bib40","first-page":"1","article-title":"Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model","author":"Cui","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2006.06.002_bib41","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1084\/jem.194.6.863","article-title":"Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens","volume":"Vol.194","author":"Kadowaki","year":"2001","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.vaccine.2006.06.002_bib42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nri1396","article-title":"Therapeutics targeting the innate immune system","volume":"4","author":"Ulevitch","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"10.1016\/j.vaccine.2006.06.002_bib43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1211\/jpp.58.4.0003","article-title":"Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice","volume":"58","author":"Sloat","year":"2006","journal-title":"J Pharm Pharmacol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06007055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06007055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T15:45:24Z","timestamp":1683474324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06007055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":43,"journal-issue":{"issue":"40-41","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0264410X06007055"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.06.002","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}